Tuberculosis: Again stronger than multiresistance;Tuberculose: Encore plus fort que la multirésistance

Revue des Maladies Respiratoires

Volumn 23, Issue 5 C2, 2006, Pages

  Blanc, F X ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL FEATURE; HUMAN; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; TREATMENT RESPONSE;

EID: 33845312972     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0761-8425(06)72007-1     Document Type: Article

References (13)

1. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006 ; 55 : 301-5.
2. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M, Iseman MD : Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004 ; 169 : 1103-9.
3. Yew WW, Chan CK, Leung CC, Chau CH, Tam CM, Wong PC, Lee J : Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003 ; 124 : 1476-81.
4. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, et coll. : Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006 ; 10 : 605-12.
5. Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, Bellanova S : Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J Chemother 2003 ; 15 : 66-70.
6. Codecasa LR, Ferrara G, Ferrarese M, Morandi MA, Penati V, Lacchini C, et coll. : Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respir Med 2006; 100: 1566-72.
7. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, et coll. : Moxifloxacin versus ethambutol in the first two months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 331-8.
8. von der Lippe B, Sandven P, Brubakk O : Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB). A report of ten cases. J Infect 2006 ; 52 : 92-6.
9. Fortun J, Martin-Davila P, Navas E, Perez-Elias MJ, Cobo J, Tato M, et coll. : Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005 ; 56 : 180-5.
10. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC : Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother 2005 ; 49 : 2816-21.
11. Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, et coll. : Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2005 ; 49 : 2289-93.
12. Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, Reynolds RC, Orme IM : Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005 ; 49 : 2294-301.
13. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, et coll. : A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005 ; 307 : 223-7.